Effect of RANKL on intraspinal transplantation of bone marrow mesenchymal stem cells after spinal cord injury in rats

Zong-mao ZHAO,Qing-jun ZHANG,Hai-ying LIU,Guo-zhu SUN

DOI: https://doi.org/10.3760/j:issn:1001-8050.2007.02.015

2007-01-01

Abstract:Objective To observe the effect of receptor activator of NF kappa B ligand （RANKL） on intraspinal transplantation of bone marrow mesenchymal stem cells （hBMSCs） after spinal cord injury in adult rats. Methods Sixty aduh Wistar rats, weighing 250 - 350g, were used for the experiment. They were subjected to left spinal cord hemisection, then divided into three groups ： （ 1 ） hBM- SCs group, BrdU-labeled hMSCs were injected adjacent to the injury area; （2） RANKL ＋ hBMSCs group, BrdU - labeled hMSCs with RANKL were injected adjacently to the injury area; （3） PBS group, phosphate-buffered saline （PBS） was injected adjacently to the injury area. Functional outcome measurements using the modified Tarlov score were performed at 1,7, 14, 21 and 28 days after transplantation. After the animals were killed, spinal cord sections were examined using immunohistochemical and immunofluorescence staining methods to detect if BrdU - labeled adult hBMSCs express the astrocytic marker- GFAP （glial fibriliary acidic protein） and the neuron marker-NeuN （neuronal nuclei）, and compared between the three groups. Results A statistically significant improvement in neurological function in rats that underwent hBMSCs and hBMSCs plus RANKL transplantation was found at each time point, compared with PBS injection rats. Meanwhile, a better neurological functional outcome was found in group hBMSCs ＋ RANKL than in group hMSCs at 7 and 14 days. More BrdU-NeuN and BrdU-GFAP immunoreactive hBMSCs were determined in rats that underwent hBMSCs and RANKL transplantation than hBMSCs injection only. Conclusion Intraspinal hBMSCs transplantation along with RANKL improves neurological outcome after spinal cord injury, and facilitates hBMSCs differentiation into neural cells.\r\n\r\nKey words: \r\nSpinal cord injuries;  Bone marrow mesenchymal stem cells;  Transplantation;  Receptor activator of NF - Kappa B ligand